May 31, 2009
| Response from Dr. McGowan
Thanks for your question.
The decision about what to switch to will be based on the resistance apttern of your virus. This can be determined through blood tests. For your treatment there are 2 types of resistance tests that would be useful: a genotype or a phenotype. These tests will show how much resistance your virus has developed. Resistance to truvada could cause some level of resistance to most of the medicines in the NRTI class of drugs. Also, if this was not your first treatment, it might be possible that previous resistance mutations from prior therapy would also have to be considered. Resistance to viracept may lead to significant resistance to other protease inhibitors (which include norvir and reyataz).
The key thing is to be sure that your new combinaion has the equivalent of 3 fully active medications (this can be 3 meds or combinations of partly active meds) to keep the virus shut down (undetectable viral load).
If this was your first combo, then resistance testing would help decide if the new cocktail indeed has 3 active drugs.
Get Email Notifications When This Forum Updates or Subscribe With RSS
- Most People Infected With Hiv Experience Ars Symptoms
- What Are Some Symptoms Associated With Acute Phase Hiv Infection?
- Enlarged Liver And Spleen Due To Hep C
- Men And Fellatio Hiv Risk
- How Long Can A Person Be Infected With Hiv Before Showing Signs Of Infection?
- How To Get Marinol Prescribed?
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.